9th Annual Biomarkers Congress
Cardiovascular Research Technologies (CRT) 2013 Valve and Structural Heart Revolution III


Washington, District of Columbia
http://www.crtmeeting.org/default.aspx
Cardiovascular Research Technologies (CRT) 2013 will take place 
from February 23 - 26, 2013 in Washington DC. This year’s conference 
will be the most comprehensive to date. CRT 2013 has many 
new and exciting features, including a new, cutting-edge Valve & Structural 
Heart track, in addition to its standard five subject areas -- Coronary, Endovascular, Science, Technology and Nurse & Tech. 
Also new this year will be the Essentials of Clinical Research course as well as more exciting hands-on workshops and simulations.

Schedule of Presentations:

Monday, February 25, 2013
13:00:00 Valve and Structural Heart Revolution III | TAVR COMPLICATIONS AND CHALLENGES David R. Holmes
13:00:00 Valve and Structural Heart Revolution III | Lessons from Complications: The Balloon-Expandable and Self-Expanding Transcatheter Valve Systems
13:05:00 Valve and Structural Heart Revolution III | How to Minimize Vascular Complications Augusto D. Pichard
13:10:00 Valve and Structural Heart Revolution III | Managing TAVR Rhythm Disturbances: New LBBB, Bradyarrhythmias and Temporary and Permanent Pacemakers Jeffrey J. Popma
13:15:00 Valve and Structural Heart Revolution III | What Is the Impact of Paravalvular Leak? Samir R. Kapadia
13:20:00 Valve and Structural Heart Revolution III | Stroke After TAVR: What Does the Data Show? David R. Holmes
13:30:00 Valve and Structural Heart Revolution III | Devices for Stroke Prevention
13:35:00 Valve and Structural Heart Revolution III | Post Marketing Report: Did We Reduce the Complications Rates in the Postmaketing Phase? Jodi Akin
13:40:00 Valve and Structural Heart Revolution III | Update on the Commercial Launch of TAVR in the US: Site Selection, Training, Clinical Indications, Case Volumes, and Clinical Outcomes Charanjit S. Rihal
13:45:00 Valve and Structural Heart Revolution III | Panel Discussion: How to Minimize Complications after TAVR Susheel Kodali, Jeffrey J. Popma, Augusto D. Pichard, Michael J. Mack, Samir R. Kapadia, David R. Holmes, Matthew G. Hillebrenner, Jodi Akin
14:15:00 Valve and Structural Heart Revolution III | Break
14:25:00 Valve and Structural Heart Revolution III | PERCUTANEOUS AORTIC VALVES: WHOM TO TREAT IN 2013 John C. Laschinger, Ron Waksman, John S. Sapirstein, Jeffrey J. Popma
14:30:00 Valve and Structural Heart Revolution III | FDA's Goal Lines in 2013 Sonna M. Patel-Raman
14:30:00 Valve and Structural Heart Revolution III | SAFE, REASONABLE, EFFECTIVE, NECESSARY: WHOSE LABEL IS IT?
14:35:00 Valve and Structural Heart Revolution III | CMS's Reimbursement Strategy
14:40:00 Valve and Structural Heart Revolution III | Adherence to the Labeling John C. Laschinger
14:45:00 Valve and Structural Heart Revolution III | AFTER THE FIRST APPROVAL
14:50:00 Valve and Structural Heart Revolution III | Patient Eligibility for Commercial TAVR in the US Michael J. Mack
14:55:00 Valve and Structural Heart Revolution III | TAVR Use Patterns Across the Globe
15:00:00 Valve and Structural Heart Revolution III | Cost Effectiveness of TAVR in Inoperable and High Risk Patients David J. Cohen
15:05:00 Valve and Structural Heart Revolution III | Post-Approval Studies and the STS/TVT Registry
15:10:00 Valve and Structural Heart Revolution III | Beyond the IDE Study: Post Market Surveillance Progress Report on the TVT Registry David R. Holmes
15:15:00 Valve and Structural Heart Revolution III | Appropriate Regulation of Adjunctive Devices: Embolic Protection
15:15:00 Valve and Structural Heart Revolution III | IMPROVED TECHNOLOGY: EVALUATING DEVICE MODIFICATIONS
15:20:00 Valve and Structural Heart Revolution III | Edwards Lifesciences
15:30:00 Valve and Structural Heart Revolution III | Medtronic CardioVascular
15:35:00 Valve and Structural Heart Revolution III | SURTAVI Trial Design and New Considerations Jeffrey J. Popma
15:40:00 Valve and Structural Heart Revolution III | Panel Discussion: Evaluation and Adoption of TAVR John C. Laschinger, Ron Waksman, John S. Sapirstein, Jeffrey J. Popma, Michael J. Mack, David R. Holmes, Andrew Farb, David J. Cohen, Dorothy B. Abel
16:30:00 Valve and Structural Heart Revolution III | Break
16:40:00 Valve and Structural Heart Revolution III | TRANSCATHETER MITRAL THERAPY Steven F. Bolling
16:45:00 Valve and Structural Heart Revolution III | Update on the Mitral Clip Trials Ted Feldman
16:50:00 Valve and Structural Heart Revolution III | New Considerations from Abbott Vascular Jamey Jacobs
16:55:00 Valve and Structural Heart Revolution III | What Is a Good Result and When Is It Good Enough? Steven F. Bolling
17:00:00 Valve and Structural Heart Revolution III | FDA's View on the Assessment of Safety and Effectiveness John C. Laschinger
17:05:00 Valve and Structural Heart Revolution III | Panel Discussion: Clinical Trials for 2012: Getting the Needed Data in Reasonable Time John C. Laschinger, Ted Feldman, Gregg W. Stone, Laura Mauri, Saibal Kar, Matthew G. Hillebrenner, Steven F. Bolling
17:45:00 Valve and Structural Heart Revolution III | Adjourn
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.